Search Results - "Gamblin, Tracy L"

JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma by Garcia, Patrick L, Miller, Aubrey L, Gamblin, Tracy L, Council, Leona N, Christein, John D, Arnoletti, J Pablo, Heslin, Marty J, Reddy, Sushanth, Richardson, Joseph H, Cui, Xiangqin, van Waardenburg, Robert C A M, Bradner, James E, Yang, Eddy S, Yoon, Karina J

“…Cholangiocarcinoma (CCA) is a fatal disease with a 5-year survival of <30%. For a majority of patients, chemotherapy is the only therapeutic option, and…”
Get full text

Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma by Garcia, Patrick L, Council, Leona N, Christein, John D, Arnoletti, J Pablo, Heslin, Marty J, Gamblin, Tracy L, Richardson, Joseph H, Bjornsti, Mary-Ann, Yoon, Karina J

“…Pancreatic cancer is the one of the deadliest of all malignancies. The five year survival rate for patients with this disease is 3-5%. Thus, there is a…”
Get full text

Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study by Cramer, Stuart L, Miller, Aubrey L, Pressey, Joseph G, Gamblin, Tracy L, Beierle, Elizabeth A, Kulbersh, Brian D, Garcia, Patrick L, Council, Leona N, Radhakrishnan, Rupa, Hendrix, Skyler V, Kelly, David R, Watts, Raymond G, Yoon, Karina J

“…Therapy for rhabdomyosarcoma (RMS) has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the…”
Get full text

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors by Miller, Aubrey L., Fehling, Samuel C., Garcia, Patrick L., Gamblin, Tracy L., Council, Leona N., van Waardenburg, Robert C.A.M., Yang, Eddy S., Bradner, James E., Yoon, Karina J.

“…DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor JQ1…”
Get full text

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer by Miller, Aubrey L, Garcia, Patrick L, Fehling, Samuel C, Gamblin, Tracy L, Vance, Rebecca B, Council, Leona N, Chen, Dongquan, Yang, Eddy S, van Waardenburg, Robert C A M, Yoon, Karina J

“…Gemcitabine is used to treat pancreatic cancer (PC), but is not curative. We sought to determine whether gemcitabine + a BET bromodomain inhibitor was superior…”
Get full text

FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer by Kreitzburg, Kelly M., Fehling, Samuel C., Landen, Charles N., Gamblin, Tracy L., Vance, Rebecca B., Arend, Rebecca C., Katre, Ashwini A., Oliver, Patsy G., van Waardenburg, Robert C.A.M., Alvarez, Ronald D., Yoon, Karina J.

“…Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States. Although most patients respond to frontline therapy,…”
Get full text

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma by Miller, Aubrey L, Garcia, Patrick L, Gamblin, Tracy L, Vance, Rebecca B, Yoon, Karina J

“…Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma (PDAC), but neither gemcitabine alone nor in combination…”
Get full text

Chronic Myocardial Infarction is a Substrate for Bradycardia-Induced Spontaneous Tachyarrhythmias and Sudden Death in Conscious Animals by KILLINGSWORTH, CHERYL R., WALCOTT, GREGORY P., GAMBLIN, TRACY L., GIROUARD, L.V.T., STEVEN D., SMITH, WILLIAM M., IDEKER, RAYMOND E.

“…Introduction: Patients with bradycardia can have severe tachyarrhythmias but it is unclear whether bradycardia alone can induce arrhythmias or whether an…”
Get full text

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models by Garcia, P L, Miller, A L, Kreitzburg, K M, Council, L N, Gamblin, T L, Christein, J D, Heslin, M J, Arnoletti, J P, Richardson, J H, Chen, D, Hanna, C A, Cramer, S L, Yang, E S, Qi, J, Bradner, J E, Yoon, K J

“…The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC)…”
Get full text

Abstract 4737: The combination of the BET inhibitor JQ1 and gemcitabine induces regressions in gemcitabine resistant patient-derived xenograft models of pancreatic cancer by Miller, Aubrey L., Fehling, Samuel C., Brown, Eric Josh, Heard, Eric O., Gamblin, Tracy L., Vance, Rebecca B., Yoon, Karina J.

“…Efforts to develop targeted therapies for drug resistant tumors have been relatively unsuccessful. The 5-year survival for patients with advanced pancreatic…”
Get full text

Abstract 1293: JQ1 sensitivity of patient-derived xenograft models of cholangiocarcinoma by Miller, Aubrey L., Garcia, Patrick L., Gamblin, Tracy L., Council, Leona N., Cui, Xiangqin, Bradner, James E., Yang, Eddy S., Yoon, Karina J.

“…Cholangiocarcinoma (CCA) is a lethal malignancy arising from cholangiocytes in any part of the biliary tree. The incidence of CCA has been on the rise…”
Get full text

Abstract 1779: Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models by Garcia, Patrick L., Miller, Aubrey L., Kreitzburg, Kelly, Gamblin, Tracy L., Council, Leona N., Christein, John D., Arnoletti, Pablo, Heslin, Marty, Reddy, Sushanth, Richardson, Joseph H., Yang, Eddy S., Qi, Jun, Bradner, James E., Yoon, Karina J.

“…Cholangiocarcinoma (CCA) is a lethal malignancy of the biliary epithelium that can arise in any part of the biliary tree. Surgery is the only curative…”
Get full text

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsResearch in context by Aubrey L. Miller, Samuel C. Fehling, Patrick L. Garcia, Tracy L. Gamblin, Leona N. Council, Robert C.A.M. van Waardenburg, Eddy S. Yang, James E. Bradner, Karina J. Yoon

“…Background: DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor…”
Get full text

Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study by Cramer, Stuart L, Miller, Aubrey L, Pressey, Joseph G, Gamblin, Tracy L, Beierle, Elizabeth A, Kulbersh, Brian D, Garcia, Patrick L, Council, Leona N, Radhakrishnan, Rupa, Hendrix, Skyler V, Kelly, David R, Watts, Raymond G, Yoon, Karina J

Get full text